CD34 and acute myeloid leukemia: We demonstrate here that low dose BaP, which uses BEZ at 0.1 mM (hereafter referred to as BaP 0.1 mM), when combined with VAL (VBaP) recapitulates selective killing of primary AML blasts and AML cell lines to levels that are similar to high dose BaP (BaP 0.5 mM), whilst not killing primary CD34+ve haemopoietic stem/progenitor cells (HSPCs) or healthy donor blood cells.